CD117 (c-Kit) is a tyrosine kinase receptor that is overexpressed in multiple dog tumors. There is 100% homology between the juxtamembrane domain of human and canine CD117, and many cancer-causing mutations occur in this region in both species. Thus, CD117 is an important target for cancer treatment in dogs and for comparative oncology studies. Currently, there is no monoclonal antibody (mAb) specifically designed to target the exposed region of canine CD117, although there exist some with species cross-reactivity. We panned a naïve phage display library to isolate antibodies against recombinant CD117 on whole cells. Several mAbs were isolated and were shown to bind recombinant canine CD117 at low- to sub-nanomolar affinity. Additional...
This report describes the characterisation of a monoclonal antibody (mAb), AB6, which recognises spe...
Anti-CD20 therapies have revolutionized the treatment of B-cell malignancies. Despite these advances...
There are limitations in pre-clinical settings using mice as a basis for clinical development in hum...
CD117 (c-Kit) is a tyrosine kinase receptor that is overexpressed in multiple dog tumors. There is 1...
CD117 is a transmembrane tyrosine kinase growth factor receptor expressed by a variety of normal hum...
Monoclonal antibodies are leading agents for therapeutic treatment of human diseases, but are limite...
CD117 is a transmembrane tyrosine kinase receptor encoded by the c-Kit proto-oncogene. The immunohis...
Interruption of the programmed death 1 (PD-1) / programmed death ligand 1 (PD-L1) pathway is an esta...
Abstract Background Myeloid derived suppressor cells (MDSCs) are a recently described population of ...
Cancer immunotherapies hold much promise, but their potential in veterinary settings has not yet bee...
International audienceWe isolated 11 antibodies specific for canine CD138 (cCD138) to validate the i...
Introduction: In normal hematopoietic cells, c-KIT plays an important role in proliferation, surviv...
p.158–166This report describes the characterisation of a monoclonal antibody (mAb), AB6, which recog...
AbstractImmune escape is the hallmark of carcinogenesis. This widely known mechanism is the overexpr...
Abstract Lymphoma is the most common hematological cancer in dogs. Canine diffuse large B cell lymph...
This report describes the characterisation of a monoclonal antibody (mAb), AB6, which recognises spe...
Anti-CD20 therapies have revolutionized the treatment of B-cell malignancies. Despite these advances...
There are limitations in pre-clinical settings using mice as a basis for clinical development in hum...
CD117 (c-Kit) is a tyrosine kinase receptor that is overexpressed in multiple dog tumors. There is 1...
CD117 is a transmembrane tyrosine kinase growth factor receptor expressed by a variety of normal hum...
Monoclonal antibodies are leading agents for therapeutic treatment of human diseases, but are limite...
CD117 is a transmembrane tyrosine kinase receptor encoded by the c-Kit proto-oncogene. The immunohis...
Interruption of the programmed death 1 (PD-1) / programmed death ligand 1 (PD-L1) pathway is an esta...
Abstract Background Myeloid derived suppressor cells (MDSCs) are a recently described population of ...
Cancer immunotherapies hold much promise, but their potential in veterinary settings has not yet bee...
International audienceWe isolated 11 antibodies specific for canine CD138 (cCD138) to validate the i...
Introduction: In normal hematopoietic cells, c-KIT plays an important role in proliferation, surviv...
p.158–166This report describes the characterisation of a monoclonal antibody (mAb), AB6, which recog...
AbstractImmune escape is the hallmark of carcinogenesis. This widely known mechanism is the overexpr...
Abstract Lymphoma is the most common hematological cancer in dogs. Canine diffuse large B cell lymph...
This report describes the characterisation of a monoclonal antibody (mAb), AB6, which recognises spe...
Anti-CD20 therapies have revolutionized the treatment of B-cell malignancies. Despite these advances...
There are limitations in pre-clinical settings using mice as a basis for clinical development in hum...